Oculis Receives Positive FDA Feedback for MS Drug Development

Biopharmaceutical company Oculis has announced positive feedback from the U.S. Food and Drug Administration (FDA) regarding its plans to develop Privosegtor, a drug substance intended for the treatment of acute multiple sclerosis exacerbations.

Post Share

Sources

Showing 0 of 1 sources

No articles available in your preferred languages.

1 article available in other languages below.

morgunbladidSwedish1h ago

Oculis fær jákvæð viðbrögð frá FDA vegna MS-lyfs

Líflyfjafyrirtækið Oculis hefur fengið jákvæð viðbrögð frá Matvæla- og lyfjaeftirliti Bandaríkjanna (FDA) vegna fyrirhugaðrar þróunar á lyfjaefninu Privosegtor til meðferðar við bráðum MS-köstum.

Read full article →

PERSPECTA

PERSPECTA

Oculis Receives Positive FDA Feedback for MS Drug Development

Sources

Oculis fær jákvæð viðbrögð frá FDA vegna MS-lyfs

Related Stories

South Cotabato Officials Report No New Hog Deaths, ASF Situation Under Control

Understanding Why Anesthesiologists Ask About Snoring Before Surgery

Greek Red Cross Issues Post-Wildfire Safety Guidelines

Impact of Parental Divorce on Sibling Relationships Explored

PERSPECTA